{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T14:31:05Z","timestamp":1788877865928,"version":"build-2803163510"},"reference-count":53,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.anai.2023.12.020","type":"journal-article","created":{"date-parts":[[2023,12,23]],"date-time":"2023-12-23T11:53:37Z","timestamp":1703332417000},"page":"337-343","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Navigating the atopic dermatitis toolbox"],"prefix":"10.1016","volume":"132","author":[{"given":"Archana","family":"Samynathan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan I.","family":"Silverberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.anai.2023.12.020_bib0001","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/j.jaad.2023.08.102","article-title":"Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies","volume":"90","author":"Davis","year":"2024","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.anai.2023.12.020_bib0002","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1111\/jdv.16892","article-title":"ETFAD\/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children","volume":"34","author":"Wollenberg","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"10.1016\/j.anai.2023.12.020_bib0003","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.anai.2023.03.010","article-title":"Atopic Dermatitis Yardstick update","volume":"130","author":"Boguniewicz","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"10.1016\/j.anai.2023.12.020_bib0004","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.jaad.2017.06.042","article-title":"When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council","volume":"77","author":"Simpson","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.anai.2023.12.020_bib0005","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jdin.2021.01.001","article-title":"Therapeutic education in atopic dermatitis: a position paper from the International Eczema Council","volume":"3","author":"Eichenfield","year":"2021","journal-title":"JAAD Int"},{"issue":"4","key":"10.1016\/j.anai.2023.12.020_bib0006","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/bjd.21615","article-title":"The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD\u2122): a clinical outcome measure for the severity of atopic dermatitis","volume":"187","author":"Simpson","year":"2022","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.anai.2023.12.020_bib0007","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1001\/jamadermatol.2021.1559","article-title":"Patient-reported outcomes in dermatology","volume":"158","author":"Kirby","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"8","key":"10.1016\/j.anai.2023.12.020_bib0008","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/jamadermatol.2018.1572","article-title":"Association of inadequately controlled disease and disease severity with patient-reported disease burden in adults with atopic dermatitis","volume":"154","author":"Simpson","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"5","key":"10.1016\/j.anai.2023.12.020_bib0009","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.clindermatol.2018.05.011","article-title":"Patient-reported outcomes and quality of life measures in atopic dermatitis","volume":"36","author":"Vakharia","year":"2018","journal-title":"Clin Dermatol"},{"issue":"1","key":"10.1016\/j.anai.2023.12.020_bib0010","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jaad.2022.04.040","article-title":"Single-question parent-reported global atopic dermatitis severity: a valid instrument in children","volume":"88","author":"Silverberg","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.anai.2023.12.020_bib0011","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.det.2023.02.003","article-title":"Diagnosing atopic dermatitis in skin of color","volume":"41","author":"Adawi","year":"2023","journal-title":"Dermatol Clin"},{"issue":"1","key":"10.1016\/j.anai.2023.12.020_bib0012","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.anai.2021.03.019","article-title":"Clinical phenotyping of atopic dermatitis using combined itch and lesional severity: a prospective observational study","volume":"127","author":"Chovatiya","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"10","key":"10.1016\/j.anai.2023.12.020_bib0013","doi-asserted-by":"crossref","first-page":"e817","DOI":"10.1111\/jdv.18303","article-title":"Therapeutic inertia in the management of patients with inadequately controlled atopic dermatitis","volume":"36","author":"Halioua","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.anai.2023.12.020_bib0014","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.jaad.2020.06.054","article-title":"Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial","volume":"83","author":"Paller","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.anai.2023.12.020_bib0015","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s40257-022-00702-2","article-title":"Tralokinumab plus topical corticosteroids as needed provides progressive and sustained efficacy in adults with moderate-to-severe atopic dermatitis over a 32-week period: an ECZTRA 3 post hoc analysis","volume":"23","author":"Silverberg","year":"2022","journal-title":"Am J Clin Dermatol"},{"issue":"10","key":"10.1016\/j.anai.2023.12.020_bib0016","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1111\/1346-8138.16039","article-title":"Effectiveness and safety of tacrolimus ointment combined with dupilumab for patients with atopic dermatitis in real-world clinical practice","volume":"48","author":"Matsutani","year":"2021","journal-title":"J Dermatol"},{"issue":"5","key":"10.1016\/j.anai.2023.12.020_bib0017","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.jaip.2023.03.011","article-title":"Biologic versus small molecule therapy for treating moderate to severe atopic dermatitis: clinical considerations","volume":"11","author":"Butala","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.anai.2023.12.020_bib0018","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/jdv.16724","article-title":"Incidence and risk factors for dupilumab associated ocular adverse events: a real-life prospective study","volume":"35","author":"Touhouche","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.anai.2023.12.020_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.xjidi.2021.100042","article-title":"A literature review of real-world effectiveness and safety of dupilumab for atopic dermatitis","volume":"1","author":"Kamata","year":"2021","journal-title":"JID Innov"},{"issue":"5","key":"10.1016\/j.anai.2023.12.020_bib0020","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/cea.14305","article-title":"Switching from dupilumab to tralokinumab in atopic dermatitis patients with ocular surface disease: preliminary case series","volume":"53","author":"Achten","year":"2023","journal-title":"Clin Exp Allergy"},{"issue":"3","key":"10.1016\/j.anai.2023.12.020_bib0021","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.jaad.2021.06.017","article-title":"Management of inadequate response and adverse effects to dupilumab in atopic dermatitis","volume":"86","author":"Narla","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.anai.2023.12.020_bib0022","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/ced.14207","article-title":"Acute onset of psoriasis in a patient with atopic dermatitis treated with dupilumab","volume":"45","author":"Ferrucci","year":"2020","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"10.1016\/j.anai.2023.12.020_bib0023","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1111\/bjd.18031","article-title":"Development of inflammatory arthritis and enthesitis in patients on dupilumab: a case series","volume":"181","author":"Willsmore","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.anai.2023.12.020_bib0024","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1271309","article-title":"Big data- and machine learning-based analysis of a global pharmacovigilance database enables the discovery of sex-specific differences in the safety profile of dual IL4\/IL13 blockade","volume":"14","author":"Sharif","year":"2023","journal-title":"Front Pharmacol"},{"issue":"10","key":"10.1016\/j.anai.2023.12.020_bib0025","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1007\/s13555-023-01000-3","article-title":"Comparative efficacy of targeted systemic therapies for moderate-to-severe atopic dermatitis without topical corticosteroids: an updated network meta-analysis","volume":"13","author":"Silverberg","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.anai.2023.12.020_bib0026","first-page":"1","article-title":"Comparative efficacy of systemic treatments for atopic dermatitis in adults","volume":"1","author":"Sesi","year":"2023","journal-title":"Expert Rev Clin Immunol"},{"issue":"11","key":"10.1016\/j.anai.2023.12.020_bib0027","doi-asserted-by":"crossref","first-page":"e22014","DOI":"10.1016\/j.heliyon.2023.e22014","article-title":"Short-term efficacy and safety of biologics and Janus kinase inhibitors for patients with atopic dermatitis: a systematic review and meta-analysis","volume":"9","author":"Chen","year":"2023","journal-title":"Heliyon"},{"issue":"8","key":"10.1016\/j.anai.2023.12.020_bib0028","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1080\/17425255.2023.2256227","article-title":"JAK1 inhibitors for the treatment of atopic dermatitis: a focus on pharmacokinetic considerations","volume":"19","author":"Kopelman","year":"2023","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.anai.2023.12.020_bib0029","doi-asserted-by":"crossref","unstructured":"Needle CD, Klein EJ, Gjonaj J, Nohria A, Karim M, Liu L, et al. Comparison of comorbidities and adverse events in dermatology and rheumatology patients prescribed tofacitinib: a retrospective analysis [e-pub ahead of print]. J Am Acad Dermatol. https:\/\/doi.org\/10.1016\/j.jaad.2023.11.027. Accessed December 2, 2023.","DOI":"10.1016\/j.jaad.2023.11.027"},{"issue":"4","key":"10.1016\/j.anai.2023.12.020_bib0030","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/bjd\/ljad229","article-title":"Major adverse cardiovascular events in patients with atopic dermatitis treated with oral Janus kinase inhibitors: a systematic review and meta-analysis","volume":"189","author":"Ertus","year":"2023","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.anai.2023.12.020_bib0031","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.jaad.2023.08.029","article-title":"Cardiovascular comorbidities in atopic dermatitis: potential implications for the use of Janus kinase inhibitors","volume":"89","author":"Jackson","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.anai.2023.12.020_bib0032","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s13555-023-00892-5","article-title":"A review on the safety of using JAK inhibitors in dermatology: clinical and laboratory monitoring","volume":"13","author":"Samuel","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"8","key":"10.1016\/j.anai.2023.12.020_bib0033","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s40264-020-00938-z","article-title":"Critical assessment of pharmacokinetic drug-drug interaction potential of tofacitinib, baricitinib and upadacitinib, the three approved Janus kinase inhibitors for rheumatoid arthritis treatment","volume":"43","author":"Veeravalli","year":"2020","journal-title":"Drug Saf"},{"issue":"10","key":"10.1016\/j.anai.2023.12.020_bib0034","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1002\/jcph.1858","article-title":"Effects of hepatic impairment on the pharmacokinetics of abrocitinib and its metabolites","volume":"61","author":"Wang","year":"2021","journal-title":"J Clin Pharmacol"},{"issue":"9","key":"10.1016\/j.anai.2023.12.020_bib0035","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1002\/jcph.1414","article-title":"Characterization of the effect of hepatic impairment on upadacitinib pharmacokinetics","volume":"59","author":"Trueman","year":"2019","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.anai.2023.12.020_bib0036","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/jcph.1980","article-title":"Effects of renal impairment on the pharmacokinetics of abrocitinib and its metabolites","volume":"62","author":"Wang","year":"2022","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.anai.2023.12.020_bib0037","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/jcph.1375","article-title":"Characterization of the effect of renal impairment on upadacitinib pharmacokinetics","volume":"59","author":"Mohamed","year":"2019","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.anai.2023.12.020_bib0038","article-title":"The associations between asthma and common comorbidities: a comprehensive Mendelian randomization study","volume":"10","author":"Wang","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.anai.2023.12.020_bib0039","doi-asserted-by":"crossref","unstructured":"Elhage KG, Kranyak A, Jin JQ, Haran K, Spencer RK, Smith PL, et al. Mendelian randomization studies in atopic dermatitis: a systematic review [e-pub ahead of print]. J Invest Dermatol. https:\/\/doi.org\/10.1016\/j.jid.2023.10.016. Accessed December 5, 2023.","DOI":"10.1016\/j.jid.2023.10.016"},{"issue":"2","key":"10.1016\/j.anai.2023.12.020_bib0040","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/ICO.0000000000003341","article-title":"Ocular surface disease in patients with atopic dermatitis treated with dupilumab: a prospective case-control study","volume":"43","author":"Marolo","year":"2024","journal-title":"Cornea"},{"issue":"10","key":"10.1016\/j.anai.2023.12.020_bib0041","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1016\/j.jid.2022.03.013","article-title":"T helper 2 IL-4\/IL-13 dual blockade with dupilumab is linked to some emergent T helper 17\u2012type diseases, including seronegative arthritis and enthesitis\/enthesopathy, but not to humoral autoimmune diseases","volume":"142","author":"Bridgewood","year":"2022","journal-title":"J Invest Dermatol"},{"issue":"1","key":"10.1016\/j.anai.2023.12.020_bib0042","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jaad.2023.08.025","article-title":"Joint pain in patients with atopic dermatitis receiving treatment with dupilumab: a US nationwide cohort study","volume":"90","author":"Schneeweiss","year":"2024","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.anai.2023.12.020_bib0043","first-page":"e42959","article-title":"Cutaneous T-cell lymphoma progression: a potential dupilumab pitfall","volume":"15","author":"Malick","year":"2023","journal-title":"Cureus"},{"issue":"7","key":"10.1016\/j.anai.2023.12.020_bib0044","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/ijd.16388","article-title":"Cutaneous T-cell lymphoma following dupilumab use: a systematic review","volume":"62","author":"Park","year":"2023","journal-title":"Int J Dermatol"},{"issue":"10","key":"10.1016\/j.anai.2023.12.020_bib0045","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1001\/jamadermatol.2023.2626","article-title":"Safety and efficacy of tralokinumab in older adults with moderate-to-severe atopic dermatitis: a secondary analysis","volume":"159","author":"Merola","year":"2023","journal-title":"JAMA Dermatol"},{"issue":"3","key":"10.1016\/j.anai.2023.12.020_bib0046","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s40257-022-00754-4","article-title":"Efficacy and safety of dupilumab maintained in adults \u2265 60 years of age with moderate-to-severe atopic dermatitis: analysis of pooled data from four randomized clinical trials","volume":"24","author":"Silverberg","year":"2023","journal-title":"Am J Clin Dermatol"},{"issue":"12","key":"10.1016\/j.anai.2023.12.020_bib0047","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1016\/j.jaip.2022.08.013","article-title":"Safety of biologics for atopic diseases during pregnancy","volume":"10","author":"Shakuntulla","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.anai.2023.12.020_bib0048","unstructured":"US National Library of Medicine. Post-authorization safety study in North America to monitor pregnancy and infant outcomes following administration of dupilumab during planned or unexpected pregnancy. Available at: https:\/\/clinicaltrials.gov\/study\/NCT04173442. Accessed December 5, 2023."},{"issue":"6","key":"10.1016\/j.anai.2023.12.020_bib0049","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1111\/jdv.18922","article-title":"Expert consensus on the systemic treatment of atopic dermatitis in special populations","volume":"37","author":"Adam","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.anai.2023.12.020_bib0050","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/DER.0000000000000526","article-title":"Association of atopic dermatitis with bacterial, fungal, viral, and sexually transmitted skin infections","volume":"31","author":"Ren","year":"2020","journal-title":"Dermatitis"},{"issue":"1","key":"10.1016\/j.anai.2023.12.020_bib0051","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.anai.2017.10.019","article-title":"Association between atopic dermatitis and serious cutaneous, multiorgan and systemic infections in US adults","volume":"120","author":"Narla","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"10.1016\/j.anai.2023.12.020_bib0052","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s40257-019-00445-7","article-title":"Infections in dupilumab clinical trials in atopic dermatitis: a comprehensive pooled analysis","volume":"20","author":"Eichenfield","year":"2019","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"10.1016\/j.anai.2023.12.020_bib0053","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2222\/jsv.71.45","article-title":"[Herpes zoster and subunit vaccine]","volume":"71","author":"Imafuku","year":"2021","journal-title":"Uirusu"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120623015053?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120623015053?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:33:36Z","timestamp":1761053616000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120623015053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S1081120623015053"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2023.12.020","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Navigating the atopic dermatitis toolbox","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2023.12.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}